Who owns Syndax Pharmaceuticals Inc?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of SNDX from SEC Form 13F filings across 237 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 237 institutions disclosed 98.7M shares of Syndax Pharmaceuticals Inc worth $1.83B — about 109.9% of shares outstanding; the largest disclosed holder is BlackRock, Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
237
13F holders
$1.83B
value, 2026 filers
109.9%
of shares outstanding (98.7M sh)
35
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of SNDX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 9.3M | $174.2M | 0.0% | 10.3% | +2.8% |
| 2 | Kynam Capital Management, LP | 8.2M | $153.2M | 8.5% | 9.1% | +1.2% |
| 3 | GOLDMAN SACHS GROUP INC | 5.5M | $103.8M | 0.0% | 6.2% | -5.8% |
| 4 | STATE STREET CORP | 4.7M | $87.5M | 0.0% | 5.2% | -17.8% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 4.0M | $74.3M | 0.0% | 4.4% | +0.7% |
| 6 | BANK OF AMERICA CORP /DE/ | 3.8M | $71.5M | 0.0% | 4.2% | -6.0% |
| 7 | DEERFIELD MANAGEMENT COMPANY, L.P. | 3.8M | $71.1M | 1.1% | 4.2% | 0.0% |
| 8 | FRANKLIN TEMPLETON INC | 3.5M | $36.4M | 0.0% | 3.9% | +52.4% |
| 9 | Hood River Capital Management LLC | 2.6M | $48.8M | 0.4% | 2.9% | +1.3% |
| 10 | Eversept Partners, LP | 2.4M | $45.9M | 2.5% | 2.7% | -12.7% |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 2.3M | $43.5M | 0.0% | 2.6% | -10.6% |
| 12 | KINGDON CAPITAL MANAGEMENT, L.L.C. | 2.2M | $42.2M | 3.7% | 2.5% | -10.2% |
| 13 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.2M | $41.7M | 0.0% | 2.5% | +15.6% |
| 14 | BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1.9M | $36.2M | 0.0% | 2.1% | +7.5% |
| 15 | Candriam S.C.A. | 1.7M | $31.5M | 0.1% | 1.9% | -1.5% |
| 16 | Elmind Capital, LP | 1.6M | $30.2M | 7.5% | 1.8% | -13.5% |
| 17 | TWO SIGMA INVESTMENTS, LP | 1.5M | $27.6M | 0.0% | 1.6% | -7.0% |
| 18 | LOOMIS SAYLES & CO L P | 1.3M | $25.1M | 0.0% | 1.5% | +44.6% |
| 19 | Woodline Partners LP | 1.3M | $25.0M | 0.1% | 1.5% | +6.4% |
| 20 | Aisling Capital Management LP | 1.3M | $24.8M | 8.3% | 1.5% | 0.0% |
| 21 | MILLENNIUM MANAGEMENT LLC | 1.2M | $22.9M | 0.0% | 1.4% | -40.6% |
| 22 | UBS Group AG | 1.1M | $21.5M | 0.0% | 1.3% | -39.5% |
| 23 | AQR CAPITAL MANAGEMENT LLC | 1.1M | $21.5M | 0.0% | 1.3% | +33.7% |
| 24 | ALGERT GLOBAL LLC | 1.1M | $20.9M | 0.3% | 1.2% | +5.9% |
| 25 | Parkman Healthcare Partners LLC | 1.1M | $20.8M | 1.9% | 1.2% | +26.0% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.